According to a recent LinkedIn post from Truveta, findings from Truveta Research featured in USA TODAY point to a sharp increase in prescriptions for estrogen-based hormone replacement therapy from 2018 to 2026. The post notes that one of the largest prescription increases has been in patch-based therapies, which may be contributing to current supply constraints.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that rising demand, evolving clinical guidance, and access challenges are making real-world data increasingly important in tracking treatment trends. For investors, this emphasis on real-world evidence could underscore Truveta’s positioning as a data and analytics provider to healthcare stakeholders, potentially enhancing its strategic relevance to life sciences, payers, and policymakers.
Increased visibility through mainstream media coverage such as USA TODAY may also signal growing recognition of the company’s data assets and research capabilities. While the post does not disclose financial metrics, sustained demand for data on treatment utilization and access could support future opportunities for commercial partnerships and product expansion in the health data and analytics market.